continuation- DRTE, RXSD, BRKS
RXSD.. is highly oversold, stochastic between 5 and 10.. Earnings are what is important in deciding if RXSD becomes a buy for more than a daytrade, rumours flying as to the quality of their drugs. Company says it will meet estimates, rumours have it they won't. RXSD has to put it mildly, a very bad chart. CCI and MACD actually had sell signals in the last 3 trading sessions, RSI is perhaps a bit higher than it was at the stocks low and Money flow index is sloping positively. Earnings out on October 7, giving you ample time to watch for a change of trend. If and only IF earnings are good there is a chance the stock will reach its estimated 'valuations'.. If not be prepared for a further tanking. 25% of this stock is being shorted. Luckily, you will soon have your answers.. If you buy on 'anticipatory upswing' you will know in the next 1-3 trading sessions if stochastics turn bullish and volume and price increase.
DRTE... one of my new 'favorites'.... AA+ rating by MPT review, AA by OTC Insight, 99 relative strength ranking 29% earnings surprise last quarter.
Chart is excellent with MACD bullish and Relative strength bullish.. but Stochastic suggest DRTE is overbought. DRTE has earnings out on the 14th of October.. It would be very attractive as an earnings play especially if it pulls back.
Earnings Velocity: $11 cents last quarter to $0.13 estimated this quarter to $0.15 next quarter....DRTE has very positive fundamentals. It's success already established in this country now its successful abroad as well:
Dendrite's European Success Further Accelerated
Kronenbourg, Evian, and William Pitters License Dendrite's ForceOne
Solution
MORRISTOWN, N.J.--(BUSINESS WIRE)--Aug. 20, 1998-- Dendrite International Inc.
(NASDAQ/NMS:DRTE - news), the leading supplier of enterprise-wide sales force effectiveness solutions for the pharmaceutical and Consumer Packaged Goods (CPG) industries, today announced
the signing of three new CPG clients in France - Kronenbourg, Evian, and William Pitters.
BRKS.. wow.. poor chart.. Stochastics are overbought, looks like people are expecting this to recover sometimes.. Looks to be losing money in the next year.. perhaps recovering by 3rd quarter of 1999. Looks like this can be on our list of low-priced stocks that will give 15-20% on any bounce... I would buy 1,000 shares of this and sit on in for 12-18 months. |
